secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001628280-24-021717
Event type: litigation
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion files Hatch-Waxman patent suit against Micro Labs over generic NEXLETOL
--------------------------------------------------------------------------------

- Filed May 8, 2024 in District of New Jersey against Micro Labs USA Inc. for NEXLETOL generic ANDA.
- Nine ANDA filers sent Paragraph IV certifications; lawsuit triggered 30-month FDA approval stay.
- Esperion intends to file similar suits against remaining eight ANDA filers for NEXLETOL and NEXLIZET.
- Complaint seeks injunction barring FDA approval and permanent injunction until patent expiration.
- Litigation covers Orange-listed patents; company vows to vigorously defend IP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828024021717/0001628280-24-021717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828024021717/espr-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-021717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer